Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1930007 | 0.97 | SIGMAR1 (0.31) | SIGMAR1OPRM1 | |
| SCHEMBL29788762 | 0.88 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL5509841 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL27624459 | 0.80 | TSHR (0.31) | — | |
| SCHEMBL24847108 | 0.78 | DRD2 (0.33) | — | |
| Tert-Butyl Formate SCHEMBL28268986 | 0.77 | TDP1 (0.48) | — | |
| Hydrochloric Acid SCHEMBL29896756 | 0.76 | DRD2 (0.32) | — | |
| SCHEMBL6676256 | 0.75 | — | — | |
| SCHEMBL78740 | 0.73 | — | — | |
| SCHEMBL28276506 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| CN-116354897-A | Substituted 1,2, 4-triazole, pyridine and pyrimidine derivatives and application thereof in medicines | 华东师范大学 | 2023-06-30 | — | — | CN | disclosed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| CN-111943946-B | Dihydroquinazinone carboxylic acid compound containing nitrogen heterocyclic segment and application thereof | 中国医学科学院医药生物技术研究所 | 2022-07-01 | — | — | CN | disclosed |
| WO-2021208963-A1 | BCL-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-10-21 | — | — | WO | disclosed |
| CN-111943946-A | Dihydroquinazinone carboxylic acid compound containing nitrogen heterocyclic segment and application thereof | 中国医学科学院医药生物技术研究所 | 2020-11-17 | — | — | CN | disclosed |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-05-14 | — | — | US | disclosed |
| CN-105037389-B | A kind of preparation method of rifamycin nitroimidazole coupling molecule | 丹诺医药(苏州）有限公司 | 2017-09-05 | — | — | CN | disclosed |
| CN-105037382-B | Bergenin analog derivative and its preparation method and application | 中国药科大学 | 2017-08-25 | — | — | CN | disclosed |
| CN-105037389-A | Preparation method of rifamycin-nitroiminazole coupled molecule | TENNOR THERAPEUTICS LTD | 2015-11-11 | — | — | CN | disclosed |
| CN-1193968-A | 2,3-dioxo-1,2,3,4-tetrahydro-quinoyxalinyl derivatives | NOVARTIS AG (CH) | 1998-09-23 | — | — | CN | disclosed |
| EP-0861660-A1 | Curative medicine for disease caused by infection of Helicobacter | KANEKA CORPORATION (JP) | 1998-09-02 | — | — | EP | disclosed |
| EP-0853617-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | Novartis AG (CH) | 1998-07-22 | — | — | EP | disclosed |
| WO-1997008155-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| EP-0070170-B1 | TYLOSIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1986-02-19 | — | — | EP | disclosed |
| EP-0134054-A1 | Tylosin derivatives, their preparation and pharmaceutical compositions containing them | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-03-13 | — | — | EP | disclosed |
| EP-0132895-A1 | Tylosin derivatives, their preparation and pharmaceutical compositions containing them | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-02-13 | — | — | EP | disclosed |
| US-4477443-A | INCREASED ANTIBIOTIC ACTIVITY | Zaidan Hojin Biselbutsu Kagaku Kenkyu Kai (Microbial Chemistry Research Foundation) (JP) | 1984-10-16 | — | — | US | disclosed |
| EP-0070170-A1 | Tylosin derivatives, their preparation and pharmaceutical compositions containing them | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1983-01-19 | — | — | EP | disclosed |
| EP-0005541-A2 | Substituted piperidine, morpholine or piperidone derivatives, fungicides containing these compounds, process for their preparation and their use, and the use of these compounds as fungicides | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159522-A1 | BCL-2 INHIBITOR | BCL2, BCL2A1, BCL2L1 | SIGMAR1 4650/4885OPRM1 4717/4885KDM4E 4044/4885 |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, MAP1LC3B | SIGMAR1 3595/4885OPRM1 3701/4885KDM4E 4066/4885 |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | SIGMAR1 3905/4885OPRM1 3670/4885KDM4E 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.